C. Bloomfield

发表

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

J. Mesirov, E. Lander, D. Slonim, 1999, Science.

C. Bloomfield, K. Mrózek, N. Heerema, 2004, Blood reviews.

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

Ulrich Mansmann, Guido Marcucci, Manuela Hummel, 2008, Blood.

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

Rakesh Nagarajan, Elaine R Mardis, Jack Baty, 2008, Blood.

Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics.

M. Caligiuri, C. Bloomfield, F. Wright, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Clinical significance of cytogenetics in acute myeloid leukemia.

C. Bloomfield, A. de la Chapelle, K. Mrózek, 1997, Seminars in oncology.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

C. Bloomfield, N. Harris, M. L. Le Beau, 2009, Blood.

Aberrant CpG-island methylation has non-random and tumour-type–specific patterns

M. Caligiuri, C. Bloomfield, F. Wright, 2000, Nature Genetics.

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

C. Bloomfield, J. Byrd, C. Croce, 2009, Blood.

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

C. Bloomfield, J. Byrd, M. Qumsiyeh, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.

E. Shapiro, C. Bloomfield, R. Adar, 2012, Blood.

MicroRNA expression in cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2008, The New England journal of medicine.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Bob Löwenberg, Benjamin L Ebert, Pierre Fenaux, 2017, Blood.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Clinical and functional significance of circular RNAs in cytogenetically normal AML.

C. Bloomfield, J. Byrd, S. Volinia, 2020, Blood advances.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology

M. Caligiuri, C. Bloomfield, G. Marcucci, 2000, Cancer investigation.

The Clinical Usefulness of Chromosome Abnormalities in Acute Leukemia

C. Bloomfield, 1985 .

The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia

Michael A. Freitas, Miranda L. Gardner, C. Bloomfield, 2019, Nature Communications.

Radical treatment of Hodgkin disease with radiation therapy: results of a 15-year clinical trial. The 1985 Erskine lecture.

C. Bloomfield, D. Aeppli, S. Levitt, 1987, Radiology.

Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy.

C. Bloomfield, D. Aeppli, S. Levitt, 1987, International journal of radiation oncology, biology, physics.

Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: an evaluation of the gains achieved with radical radiotherapy.

C. Bloomfield, D. Aeppli, S. Levitt, 1990, International journal of radiation oncology, biology, physics.

Risk of adult acute leukemia in relation to prior immune-related conditions.

C. Bloomfield, G. Cooper, D. Sandler, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation

C. Bloomfield, Melissa Bowman, K. Link, 2016, Proceedings of the National Academy of Sciences.

changes of myeloid neoplasms and acute leukemia: rationale and important The 2008 revision of the World Health Organization (WHO) classification

C. Bloomfield, N. Harris, M. L. Beau, 2013 .

The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes

C. Bloomfield, N. Harris, M. L. Beau, 2009 .

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

C. Bloomfield, D. Gilliland, T. Barbui, 2007, Blood.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

M. Caligiuri, C. Bloomfield, C. Croce, 2017, Proceedings of the National Academy of Sciences.

Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) ≥60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2004 .

Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21

C. Bloomfield, J. Byrd, K. Mrózek, 2019, Leukemia.

Introduction: acute leukemia: recent advances.

M. Caligiuri, C. Bloomfield, G. Herzig, 1997, Seminars in oncology.

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement

C. Bloomfield, J. Byrd, R. Garzon, 2021, Journal of Hematology & Oncology.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

C. Bloomfield, M. Grever, J. Byrd, 2010, Proceedings of the National Academy of Sciences.

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

C. Bloomfield, R. Larson, W. Stock, 2014 .

Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene

M. Caligiuri, C. Bloomfield, C. Plass, 1999, Oncogene.

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Guido Marcucci, Christian Buske, Michael Unterhalt, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

M. Caligiuri, C. Bloomfield, R. Larson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.

C. Bloomfield, R. Vij, R. Larson, 2010, Blood.

High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.

C. Bloomfield, M. Radmacher, E. Thiel, 2011, Leukemia research.

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Grever, 2012, Blood.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

C. Bloomfield, M. Millenson, H. Deeg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Myelodysplastic SyndromesPractice Guidelines in Oncology

C. Bloomfield, M. Millenson, H. Deeg, 2011 .

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).

C. Bloomfield, H. Deeg, K. Mrózek, 2021, Blood advances.

Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)

C. Bloomfield, E. Moodie, K. Mrózek, 2018, Cancer medicine.

Granulocyte Transfusion: A Controlled Study in Patients with Acute Nonlymphocytic Leukemia

C. Bloomfield, C. Bloomfield, B. Kennedy, 2003 .

Controversies in transfusion medicine

C. Bloomfield, M. Baer, 1992, Transfusion.

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia

C. Bloomfield, R. Larson, K. Mrózek, 2013, Cancer.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

C. Bloomfield, R. Larson, K. Mrózek, 2019, Blood.

Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes

Christopher A. Miller, Matthew J. Schuelke, R. Fulton, 2021, Proceedings of the National Academy of Sciences.

B 8461 older with acute myeloid leukemia: results from cancer and leukemia group complete remission and long-term outcome in patients 60 years of age or Pretreatment cytogenetics add to other prognostic factors predicting

C. Bloomfield, M. Qumsiyeh, R. Larson, 2011 .

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

The role of heredity in cancer.

C. Bloomfield, R. King, E. Levine, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.

C. Bloomfield, J. Hansen, R. Good, 1973, The Journal of clinical investigation.

Low cancer incidence rates in Ohio Amish

S. MacEachern, C. Bloomfield, S. Lemeshow, 2009, Cancer Causes & Control.

No evidence for microsatellite instability in acute myeloid leukemia

C. Bloomfield, A. de la Chapelle, K. Mrózek, 2017, Leukemia.

international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization

C. Bloomfield, T. Barbui, S. Verstovsek, 2009 .

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

C. Bloomfield, F. Appelbaum, R. Stone, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

C. Bloomfield, R. Bejar, P. Greenberg, 2015 .

Myelodysplastic syndromes clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Ashley D. Hill, M. Loh, J. Downing, 2019, Nature Genetics.

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

C. Bloomfield, Cheng Cheng, J. Radich, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.

C. Bloomfield, C. Willman, M. Tallman, 2013, Leukemia research.

Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.

C. Bloomfield, T. Pajak, N. Nissen, 1982, Cancer treatment reports.

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia

C. Bloomfield, J. Byrd, K. Metzeler, 2021, Haematologica.

Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia

C. Bloomfield, J. Byrd, S. Volinia, 2019, Molecular Cancer Therapeutics.

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2017, Haematologica.

Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2003 .

Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia

C. Bloomfield, E. Thiel, W. Hofmann, 2009, Haematologica.

Physical Activity Among Amish and Non-Amish Adults Living in Ohio Appalachia

C. Bloomfield, M. Katz, E. Paskett, 2012, Journal of Community Health.

Complementary and Alternative Medicine Use Among Amish and Non-Amish Residents of Ohio Appalachia

C. Bloomfield, M. Katz, E. Paskett, 2009 .

Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013

C. Bloomfield, R. Larson, W. Stock, 2003, Leukemia & lymphoma.

Treatment of Biologically Determined Subsets of Acute Lymphoblastic Leukemia in Adults: Cancer and Leukemia Group B Studies

C. Bloomfield, R. Larson, R. Dodge, 1997 .

Cancer and Leukemia Group B Studies in Acute Lymphoblastic Leukemia

C. Bloomfield, R. Larson, C. Schiffer, 1994 .

In vitro glucocorticoid studies in human lymphoma: clinical and biologic significance.

C. Bloomfield, K. Smith, A. Munck, 1981, Journal of steroid biochemistry.

IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA

C. Bloomfield, Kendall A. Smith, A. Munck, 1980, The Lancet.

Combination versus successive single agent chemotherapy in lymphocytic lymphoma

Mayo, C. Bloomfield, D. Kiang, 1978, Cancer.

The role of radiation therapy in the treatment of early stage large cell lymphoma

C. Bloomfield, S. Levitt, G. Frizzera, 1985, Hematological oncology.

The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997

C. Bloomfield, J. Diebold, N. Harris, 2000, Modern Pathology.

and whites with acute myeloid leukemia Differences in prognostic factors and outcomes in African Americans

Edward J. Lee, C. Bloomfield, R. Larson, 2011 .

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.

C. Bloomfield, R. Larson, W. Stock, 2008, Blood.

ADVANCES IN LLM

C. Bloomfield, P. Porcu, 2005 .

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Haematologica.

Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia

Michael C. Rusch, M. Loh, J. Downing, 2013 .

The philadelphia chromosome in acute leukemia

C. Bloomfield, J. Yunis, R. Brunning, 1978, Virchows Archiv. B, Cell pathology.

Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic diseases.

C. Bloomfield, J. Kersey, P. Coccia, 1977, Clinical immunology and immunopathology.

Cytochemical profiles in acute lymphoblastic leukemia

C. Bloomfield, R. Brynes, J. Kersey, 1979 .

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

C. Bloomfield, J. Byrd, S. Liyanarachchi, 2019, Clinical Cancer Research.

E01 Biology, cytogenetics and molecular studies in acute myeloid leukemia

C. Bloomfield, P. Paschka, K. Mrózek, 2007 .

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

C. Bloomfield, J. Byrd, K. Mrózek, 2016, British journal of haematology.

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

C. Bloomfield, J. Byrd, S. Liyanarachchi, 2018, Leukemia.

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2007 .

The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis.

C. Bloomfield, S. Fröhling, W. Hiddemann, 2007 .

Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia

C. Bloomfield, Yusuke Nakamura, R. Larson, 2016, The Pharmacogenomics Journal.

High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia.

C. Bloomfield, B. Peterson, 1978, Medical and pediatric oncology.

Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas.

C. Bloomfield, T. Tsuruo, M. Wick, 1992, Cancer research.

Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.

M. Caligiuri, C. Bloomfield, S. Knuutila, 1996, Blood.

The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Recurring chromosome abnormalities in Hodgkin's disease

C. Bloomfield, H. Döhner, D. Arthur, 1992, Genes, chromosomes & cancer.

Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy.

C. Bloomfield, L. Blumenson, K. Mrózek, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nodular lymphoma: Bone marrow and blood manifestations

C. Bloomfield, R. Brunning, R. Mckenna, 1975, Cancer.

Correlations between immunological phenotype and karyotype in malignant lymphoma.

C. Bloomfield, D. Arthur, T. Lebien, 1986, Cancer research.

There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas

C. Bloomfield, D. Arthur, B. Peterson, 1985 .

Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma.

C. Bloomfield, D. Arthur, B. Peterson, 1988, Annals of internal medicine.

Multidrug resistance in acute myeloid leukemia.

C. Bloomfield, M. Baer, 1991, Journal of the National Cancer Institute.

Abstracts of workshop presentations (Part 6 of 16)

J. N. Guidi, C. Bloomfield, K. Kidd, 1987 .

Golub , Monitoring and Class Prediction by Gene Expression Molecular Classification of Cancer : Class Discovery

J. Mesirov, E. Lander, D. Slonim, 2007 .

Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts.

C. Bloomfield, L. Blumenson, H. Baumann, 1998, Leukemia & lymphoma.

B and T cell lymphomas. Analysis of blood and lymph nodes in 87 patients.

C. Bloomfield, J. Kersey, R. Brunning, 1975, The American journal of medicine.

Predictability of immunologic phenotype of malignant lymphomas by conventional morphology. A study of 60 cases

C. Bloomfield, J. Kersey, K. Gajl-Peczalska, 1979, Cancer.

Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?

C. Bloomfield, A. de la Chapelle, K. Mrózek, 2019, Leukemia.

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.

C. Bloomfield, C. Schiffer, R. Mayer, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trisomy 13 in acute leukemia.

C. Bloomfield, M. Baer, Maria R. Baer, 1992, Leukemia & lymphoma.

Cytogenetics and oncogenes in leukemia

C. Bloomfield, M. Baer, Clara D. Bloomfield, 1992, Current opinion in oncology.

Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia?

J. Pankow, C. Bloomfield, A. Olshan, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

C. Bloomfield, K. Owzar, R. Vij, 2013, Investigational New Drugs.

Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583

C. Bloomfield, J. Testa, S. George, 1993 .

Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia.

C. Bloomfield, J. Fay, Y. Rustum, 1996, Blood.

The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, G. Marcucci, 1998, Proceedings of the National Academy of Sciences of the United States of America.

An altered 11-kilobase transcript in leukemic cell lines with the t(4;11)(q21;q23) chromosome translocation.

P. Nowell, C. Bloomfield, T. Nakamura, 1992, Cancer research.

Cyclophosphamide, doxorubicin, vincristine, and low‐dose continuous infusion bleomycin in non‐Hodgkin's lymphoma: Cancer and leukemia group B study #7804

C. Bloomfield, T. Pajak, J. Blom, 1982 .

Chapter 14 – NITROSOUREAS IN THE THERAPY OF HODGKIN'S DISEASE

C. Bloomfield, T. Pajak, N. Nissen, 1981 .

Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.

C. Bloomfield, E. Levine, Bloomfield Cd, 1992, Seminars in oncology.

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Clinical Cancer Research.

Tobacco use among the Amish in Holmes County, Ohio.

Ross M. Kauffman, C. Bloomfield, S. Lemeshow, 2008, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

Acute leukemia and residential proximity to potential sources of environmental pollutants.

C. Bloomfield, D. Sandler, F. Davey, 1993, Archives of environmental health.

Therapy‐related leukemia. A panmyelosis

C. Bloomfield, K. Foucar, R. Brunning, 1979, Cancer.

Blast crisis as an initial or terminal manifestation of chronic myeloid leukemia. A study of 28 patients.

C. Bloomfield, L. Peterson, R. Brunning, 1976, The American journal of medicine.

Prognostic implications of cytology in acute leukemia in the adult: the case for subacute leukemia.

C. Bloomfield, R. Brunning, 1974, Human pathology.

Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss‐of‐function mutations

M. Caligiuri, C. Bloomfield, S. Fröhling, 2005, Genes, chromosomes & cancer.

Adult de novo acute myeloid leukemia with t(6;11)(q27;q23)

C. Bloomfield, R. Larson, K. Mrózek, 2004, Cancer.

Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.

C. Bloomfield, R. Larson, K. Mrózek, 2004, Cancer.

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

C. Bloomfield, K. Mrózek, R. Mayer, 1997, Blood.

There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas.

C. Bloomfield, D. Arthur, B. Peterson, 1985, Blood.

Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.

C. Bloomfield, C. Willman, M. Tallman, 2000, Blood.

Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions.

M. Caligiuri, C. Bloomfield, G. Marcucci, 1997, Blood.

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

C. Bloomfield, R. Vij, R. Larson, 2005 .

Effect of age on therapeutic response and survival in advanced Hodgkin's disease.

C. Bloomfield, T. Pajak, N. Nissen, 1982, Cancer treatment reports.

Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

C. Bloomfield, F. Appelbaum, R. Stone, 2014 .

Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.

Edward J. Lee, C. Bloomfield, G. Petroni, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

C. Bloomfield, R. Larson, G. Lozanski, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B.

C. Bloomfield, B. Peterson, F. Davey, 1997, Leukemia research.

Prognostic impact of the CD34+/CD38− cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation

C. Bloomfield, K. Mrózek, G. Behre, 2017, American journal of hematology.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

C. Bloomfield, J. Diebold, N. Harris, 2000, The hematology journal : the official journal of the European Haematology Association.

Prognostic factors for selecting curative therapy for adult acute myeloid leukemia.

C. Bloomfield, 1992, Leukemia.

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

C. Bloomfield, R. Larson, F. Appelbaum, 2012, Blood.

Treatment-inﬂuenced associations of PML-RAR (cid:1) mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

C. Bloomfield, R. Larson, F. Appelbaum, 2012 .

Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia.

C. Bloomfield, A. de la Chapelle, A. Goldman, 1984, Cancer genetics and cytogenetics.

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

C. Bloomfield, K. Döhner, R. Schlenk, 2021, Leukemia.

Response: Conflicting data on the prognostic significance of FLT3-TKD mutations in cytogenetically normal acute myeloid leukemia (CN-AML) might be related to many factors, including techniques used to detect FLT3-TKD, differences in patient populations studied, and treatment regimens

C. Bloomfield, K. Mrózek, G. Marcucci, 2008 .

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Acute leukemia as a terminal event in nonleukemic hematopoietic disorders.

C. Bloomfield, R. Brunning, 1976, Seminars in oncology.

Morphology of chronic lymphocytic leukemia and its relationship to survival.

C. Bloomfield, L. Peterson, R. Brunning, 1975, The American journal of medicine.

Monoclonal antibody MCS-2 as the marker of phorbol diester-induced myeloid differentiation in acute undifferentiated leukemia.

C. Bloomfield, T. Lebien, R. Brunning, 1984, Cancer research.

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

C. Bloomfield, R. Larson, K. Mrózek, 2016, Leukemia.

Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan

C. Bloomfield, R. Larson, Daohai Yu, 2009, Cancer.

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2014, Leukemia.

Reply to K. Orendi et al.

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

C. Bloomfield, R. Larson, K. Mrózek, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

C. Bloomfield, M. Buyse, R. Larson, 2011, Blood.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007, Blood.

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

C. Bloomfield, K. Döhner, R. Schlenk, 2017 .

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

C. Bloomfield, L. Bullinger, K. Döhner, 2022, Leukemia.

Intensive five‐drug combination chemotherapy for adult acute non‐lymphocytic leukemia

C. Bloomfield, G. Bosl, B. Peterson, 1980, Cancer.

Induction of differentiation in blast cells and leukemia colony-forming cells from patients with acute myeloid leukemia.

C. Bloomfield, T. Stukel, F. Davey, 1990, Blood.

ras oncogene activation and occupational exposures in acute myeloid leukemia.

C. Bloomfield, J. Taylor, E. Liu, 1992, Journal of the National Cancer Institute.

Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.

C. Bloomfield, R. Larson, Daohai Yu, 2006, International journal of oncology.

Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT–PCR useful clinically?

M. Caligiuri, C. Bloomfield, G. Marcucci, 2003, European journal of haematology.

Chromosome abnormalities in peripheral T‐cell lymphoma

C. Bloomfield, K. Franssila, S. Knuutila, 1987, British journal of haematology.

Curative radiotherapy for localized diffuse histiocytic lymphoma.

C. Bloomfield, S. Levitt, G. Frizzera, 1980, Cancer treatment reports.

Abnormal immunoregulation in patients with non-Hodgkin's malignant lymphomas. I. Increased helper function of peripheral blood T lymphocytes.

C. Bloomfield, K. Gajl-Peczalska, S. Chartrand, 1982, Clinical immunology and immunopathology.

PROGNOSTIC SIGNIFICANCE OF LYMPHOCYTE SURFACE MARKERS IN ADULT NON-HODGKIN'S MALIGNANT LYMPHOMA

C. Bloomfield, J. Kersey, R. Brunning, 1976, The Lancet.

Incidence, cytology, and histopathology of non‐Hodgkin's lymphomas in the bone marrow

C. Bloomfield, R. Brunning, F. Dick, 1974, Cancer.

Abstracts of workshop presentations (Part 2 of 16)

J. N. Guidi, C. Bloomfield, K. Kidd, 1987 .

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

George A Calin, Steven M Kornblau, Muller Fabbri, 2008, Blood.

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.

C. Bloomfield, C. Croce, S. Volinia, 2014, Blood.

-mutated AML NPM1 Implications of the miR-10 family in chemotherapy response of

C. Bloomfield, C. Croce, S. Volinia, 2014 .

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

C. Bloomfield, J. Byrd, R. Vij, 2009 .

Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia

C. Bloomfield, O. Garson, R. Berger, 1986 .

5-Azacytidine and renal tubular dysfunction.

C. Bloomfield, A. Collins, N. Vogelzang, 1981, Blood.

Nosocomial septicemia in the cancer patient: the influence of central venous access devices, neutropenia, and type of malignancy.

C. Bloomfield, V. Morrison, B. Peterson, 1990, Medical and pediatric oncology.

Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.

C. Bloomfield, J. Anderson, A. Gottlieb, 1988, Medical and pediatric oncology.

Health Literacy Among the Amish: Measuring a Complex Concept Among a Unique Population

C. Bloomfield, M. Katz, E. Paskett, 2013, Journal of Community Health.

DIVERSITY OF PHENOTYPES OF NON-HODGKIN'S MALIGNANT LYMPHOMA

C. Bloomfield, T. Lebien, J. Kersey, 1982 .

Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment.

C. Bloomfield, T. Lebien, J. Kersey, 1988, The American journal of medicine.

Abstracts of workshop presentations (Part 12 of 16)

J. N. Guidi, C. Bloomfield, K. Kidd, 1987 .

Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia.

C. Bloomfield, J. Machnicki, 1990, Clinics in laboratory medicine.

A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851.

C. Bloomfield, L. Norton, A. Gottlieb, 1987, NCI monographs : a publication of the National Cancer Institute.

Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma.

C. Bloomfield, J. Kersey, R. Brunning, 1977, Cancer treatment reports.

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

C. Bloomfield, J. Byrd, R. Larson, 2006 .

Glucocorticoid receptors in chronic lymphocytic leukemia.

C. Bloomfield, K. Smith, B. Peterson, 1985, Leukemia research.

Acute myeloid leukaemia in 2012: En route to improved treatment options

C. Bloomfield, H. Becker, 2013, Nature Reviews Clinical Oncology.

Combined chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP

C. Bloomfield, B. Kennedy, R. Weiss, 1976 .

Phenotypes of Adult Acute Lymphoblastic Leukemia Defined by Monoclonal Antibodies

C. Bloomfield, T. Lebien, J. Minowada, 1984 .

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

C. Bloomfield, J. Byrd, K. Mrózek, 2019, Leukemia.

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

C. Bloomfield, J. Byrd, A. de la Chapelle, 2018, Leukemia.

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485

M. Caligiuri, C. Bloomfield, M. Grever, 2017, Haematologica.

Surface markers define human lymphoid malignancies with differing prognoses.

C. Bloomfield, J. Kersey, R. Brunning, 1977, Haematology and blood transfusion.

Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.

M. Caligiuri, C. Bloomfield, G. Marcucci, 2013, Blood.

Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2005 .

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

C. Bloomfield, R. Larson, F. Appelbaum, 2006 .

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

C. Bloomfield, R. Vij, R. Larson, 2013 .

The clinical significance of chromosomal changes in childhood acute leukemia

C. Bloomfield, 1985 .

Chromosomal abnormalities in acute lymphoblastic leukemia.

C. Bloomfield, D. Arthur, T. Lebien, 1981, Cancer research.

Round Cell Liposarcoma With the Insertion (12;16)(ql3;pll.2pl3)

C. Bloomfield, C. Karakousis, J. Brooks, 2015 .

Cytogenetic Subtype Cytarabine Intensification in Acute Myeloid Leukemia Varies by Frequency of Prolonged Remission Duration after High-Dose Updated

C. Bloomfield, J. Byrd, S. Patil, 2006 .

Nonrandom Chromosome Abnormalities in Lymphoma 1

C. Bloomfield, D. Arthur, B. Peterson, 2006 .

Low Incidence of TALl Gene Rearrangements in Adult Acute Lymphoblastic Leukemia : A Cancer and Leukemia

Larson, C. Bloomfield, R. Dodge, 2005 .

Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B

M. Caligiuri, C. Bloomfield, J. Byrd, 2001 .

Cytogenetics of uterine sarcomas: presentation of eight new cases and review of the literature.

C. Bloomfield, K. Mrózek, N. Mandahl, 1998, Gynecologic oncology.

Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3.

C. Bloomfield, C. Karakousis, K. Mrózek, 1993, Cancer research.

Banded chromosome abnormalities in non-Hodgkin’s lymphoma. Correlations with morphology, immunologic phenotype and clinical course

C. Bloomfield, D. Arthur, T. Lebien, 1985 .

Chromosome abnormalities in malignant lymphoma: biologic and clinical correlations.

C. Bloomfield, D. Arthur, T. Lebien, 1985, Haematology and blood transfusion.

Familial Hodgkin's Disease and the Major Histocompatibility Complex

C. Bloomfield, E. Yunis, C. Moldow, 1977, Vox sanguinis.

Use of Monoclonal Antibodies, Morphology, and Cytochemistry to Probe the Cellular Heterogeneity of Acute Leukemia and Lymphoma1

C. Bloomfield, T. Lebien, J. Kersey, 2006 .

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Heather L. Mulder, Erin K. Hedlund, Michael C. Rusch, 2014, The New England journal of medicine.

Daunorubicin therapy in adult acute lymphatic leukemia

C. Bloomfield, B. Kennedy, R. Brunning, 1972, Cancer.

Glucocorticoid receptors in adult acute lymphoblastic leukemia.

C. Bloomfield, K. Smith, A. Munck, 1981, Cancer research.

Treatment of acute nonlymphocytic leukemia in elderly patients. A prospective study of intensive chemotherapy

C. Bloomfield, B. Peterson, 1977, Cancer.

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

C. Bloomfield, R. Larson, Daohai Yu, 2005 .

t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic- clinicopathologic association

C. Bloomfield, O. Garson, S. Knuutila, 1985 .

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.

C. Bloomfield, R. Larson, F. Appelbaum, 2006 .

Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.

C. Bloomfield, R. Advani, P. Bierman, 2006, The Journal of the National Comprehensive Cancer Network.

Interferon therapy of relapsed and refractory Hodgkin's disease: Cancer and Leukemia Group B Study 8652.

C. Bloomfield, M. Rybak, A. Gottlieb, 1990, Journal of biological response modifiers.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma.

C. Bloomfield, R. Miller, I. Royston, 1991, Blood.

Long-term disease-free survival in acute nonlymphocytic leukemia.

C. Bloomfield, B. Peterson, 1981, Blood.

Uncommon patterns of presentation of leukemia

C. Bloomfield, M. Baer, C. Vidal, 1999, Hematological oncology.

FAB M7: acute megakaryoblastic leukemia--beyond morphology.

C. Bloomfield, R. Brunning, 1985, Annals of internal medicine.

Long‐term survival of patients with acute myeloid leukemia

C. Bloomfield, J. Rowley, O. Garson, 1997, Cancer.

Abstracts of workshop presentations (Part 10 of 16)

J. N. Guidi, C. Bloomfield, K. Kidd, 1987 .

t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association.

C. Bloomfield, A. de la Chapelle, O. Garson, 1985, Blood.

Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

C. Bloomfield, J. Testa, S. George, 1993, Blood.

Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

C. Bloomfield, K. Mrózek, M. Perales, 2020, International journal of laboratory hematology.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2014, The Journal of clinical investigation.

Double Esterase Staining andOther Neutrophilic Granule Abnormalities in 237 Patients with the Myelodysplastic Syndrome Studied by the Cancer and Leukemia Group B

C. Bloomfield, B. Peterson, F. Davey, 1998, Acta Haematologica.

The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells.

C. Bloomfield, F. Davey, M. Elghetany, 1992, American journal of clinical pathology.

Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells.

C. Bloomfield, J. Griffin, J. Mcdermott, 1989, Blood.

All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia

C. Bloomfield, F. Appelbaum, C. Willman, 2001 .

Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.

M. Caligiuri, C. Bloomfield, C. Croce, 1996, Cancer research.

Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia.

C. Bloomfield, R. Larson, C. Schiffer, 1992 .

Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance.

C. Bloomfield, D. Arthur, M. Nesbit, 1982, Blood.

Acute monoblastic leukemia: diagnosis and treatment of ten cases.

C. Bloomfield, R. Brunning, M. Nesbit, 1975, Blood.

Translocation t(12;22)(q13;q12.2–12.3) in a clear cell sarcoma of tendons and aponeuroses

C. Bloomfield, K. Mrózek, C. Karakousis, 1993, Genes, chromosomes & cancer.

Nonrandom chromosome abnormalities in lymphoma.

C. Bloomfield, D. Arthur, B. Peterson, 1983, Cancer research.

A NUMBER OF recurring chromosome translocations

C. Bloomfield, S. Knuutila, L. Volin, 2011 .

Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults

C. Bloomfield, D. Arthur, V. Morrison, 1994, American journal of hematology.

Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia.

C. Bloomfield, R. Larson, C. Schiffer, 1992, Leukemia.

Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia.

C. Bloomfield, J. Rowley, A. de la Chapelle, 1989, Cancer genetics and cytogenetics.

The clinical use of cytogenetics in acute leukemia.

C. Bloomfield, M. Baer, 1991, Annals of medicine.

VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.

C. Bloomfield, N. Nissen, J. Blom, 1980, Cancer treatment reports.

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

C. Bloomfield, T. Pajak, N. Nissen, 1980, Cancer.

Cephalothin, carbenicillin, and gentamicin combination therapy for febrile patients with acute non‐lymphocytic leukemia

C. Bloomfield, B. Kennedy, Clara D. Bloomfield, 1974, Cancer.

The clinical significance of biological characteristics of the cells in acute myeloid leukemia.

C. Bloomfield, M. Baer, 1991, Annual review of medicine.

A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia.

C. Bloomfield, J. Connett, R. Strauss, 1981, New England Journal of Medicine.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

C. Bloomfield, C. Schiffer, R. Larson, 2001, Blood.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

C. Bloomfield, M. Grever, B. Cheson, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

C. Bloomfield, R. Larson, S. George, 2005, Blood.

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

C. Bloomfield, J. Byrd, M. Qumsiyeh, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

C. Bloomfield, J. Byrd, S. Patil, 1998, Cancer research.

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia

C. Bloomfield, J. Byrd, K. Coombes, 2021, Genome research.

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq

C. Bloomfield, J. Byrd, N. Heerema, 2021, Leukemia.

Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.

C. Bloomfield, K. Döhner, R. Schlenk, 2019, Blood.

Time to repeal and replace response criteria for acute myeloid leukemia?

C. Bloomfield, L. Pleyer, E. Estey, 2018, Blood reviews.

Acute myeloid leukaemia

Asim Khwaja, Rosemary E. Gale, David C. Linch, 2016, Nature Reviews Disease Primers.

Chronic and Acute Leukemias in Adults

C. Bloomfield, 2012, Cancer Treatment and Research.

Neutrophil function in lymphoreticular malignancy

C. Bloomfield, R. Nelson, R. Brunning, 1979, Cancer.

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

G Flandrin, J Diebold, C. Bloomfield, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.

G Flandrin, J Diebold, C. Bloomfield, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Sister chromatid exchange in lymphocytes from patients with malignant lymphoma

C. Bloomfield, J. Červenka, S. Levitt, 1978, Human Genetics.

Adult Leukemias 1

C. Bloomfield, 1982, Cancer Treatment and Research.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Mario Cazzola, Robert Hasserjian, C. Bloomfield, 2016, Blood.

Acute Myeloid Leukemia.

Daniel J Weisdorf, Hartmut Döhner, C. Bloomfield, 2015, The New England journal of medicine.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

C. Bloomfield, E. Estey, W. Hiddemann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

C. Bloomfield, N. Nissen, K. Rai, 1981, Blood.

Acute Promyelocytic Leukemia: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

C. Bloomfield, A. Collins, B. Peterson, 1978 .

Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

C. Bloomfield, A. Collins, B. Peterson, 1978 .

Cytogenetics in Acute Leukemia

C. Bloomfield, K. Mrózek, N. Heerema, 2022 .

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol

C. Bloomfield, W. Woods, F. Appelbaum, 2022 .

Acute nonlymphocytic leukemia in patients with nodular lymphoma

C. Bloomfield, A. Collins, B. Peterson, 1977, Cancer.

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

C. Bloomfield, R. Larson, J. Kurtzberg, 2005, Blood.

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Guido Marcucci, M. Caligiuri, C. Bloomfield, 2005, Cancer cell.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

C. Bloomfield, J. Byrd, R. Larson, 2002, Blood.

Daunorubicin-prednisone treatment of erythroleukemia.

C. Bloomfield, B. Kennedy, R. Brunning, 1974, Annals of internal medicine.

Severe renal tubular dysfunction during 5-azacytidine chemotherapy

C. Bloomfield, A. Collins, N. Vogelzang, 1979 .

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

M. Caligiuri, C. Bloomfield, R. Larson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

M. Caligiuri, C. Bloomfield, R. Larson, 2002, Blood.

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

Edward J. Lee, C. Bloomfield, S. George, 2001, Blood.

The Clinical Relevance of Lymphocyte Surface Markers in Adult Acute Lymphoblastic Leukemia

C. Bloomfield, 1982 .

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, Lisheng Wang, 2007, Blood.

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.

Guido Marcucci, M. Caligiuri, C. Bloomfield, 2006, Blood.

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.

C. Bloomfield, E. Thiel, G. Ehninger, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.

M. Caligiuri, C. Bloomfield, C. Plass, 2005, Blood.

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, R. Larson, 2001, Cancer research.

Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia

C. Bloomfield, C. Schiffer, S. George, 1994 .

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

R M Stone, S L George, M. Caligiuri, 2011, Leukemia.

Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

C. Bloomfield, G. Tricot, S. Waxman, 2002, The oncologist.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2010, Cancer cell.

Myelodysplastic syndromes.

C. Bloomfield, M. Millenson, H. Deeg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

All-trans-retinoic acid in acute promyelocytic leukemia.

C. Bloomfield, F. Appelbaum, C. Willman, 1997, The New England journal of medicine.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

C. Bloomfield, K. Döhner, R. Schlenk, 2017, The New England journal of medicine.

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study

C. Bloomfield, G. Rosner, R. Schilsky, 1995, Cancer Chemotherapy and Pharmacology.

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Edward J. Lee, M. Caligiuri, C. Bloomfield, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

M. Caligiuri, C. Bloomfield, R. Vij, 2013, Cancer.

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

C. Bloomfield, P. Paschka, K. Mrózek, 2007, Blood.

All patients with acute nonlymphocytic leukemia may have a chromosomal defect.

C. Bloomfield, J. Yunis, K. Ensrud, 1981, The New England journal of medicine.

BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia

M. Caligiuri, C. Bloomfield, C. Plass, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, C. Croce, 2000, Proceedings of the National Academy of Sciences of the United States of America.

of chromosome 11 loci Novel methylation targets in de novo acute myeloid leukemia with prevalence

M. Caligiuri, C. Bloomfield, F. Wright, 2010 .

Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci.

M. Caligiuri, C. Bloomfield, F. Wright, 2001, Blood.

The prognostic and functional role of microRNAs in acute myeloid leukemia.

Guido Marcucci, C. Bloomfield, M. Radmacher, 2011, Blood.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Christian Langer, Guido Marcucci, M. Caligiuri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

C. Bloomfield, M. Ross, M. Radmacher, 2008, Blood.

MicroRNA fingerprints during human megakaryocytopoiesis.

George A Calin, Guido Marcucci, Stefano Volinia, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

C. Bloomfield, K. Mrózek, S. Bigner, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia.

Walker, C. Bloomfield, A. de la Chapelle, 1986, Blood.

High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults.

C. Bloomfield, E. Thiel, W. Hofmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

Guido Marcucci, C. Bloomfield, K. Mrózek, 2005, Current opinion in hematology.

Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.

Sandya Liyanarachchi, Herbert Auer, Ramana V Davuluri, 2004, Proceedings of the National Academy of Sciences of the United States of America.

BAALC, a novel marker of human hematopoietic progenitor cells.

M. Caligiuri, C. Bloomfield, Changsun Choi, 2003, Experimental hematology.

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.

M. Caligiuri, C. Bloomfield, R. Larson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.

C. Bloomfield, K. Mrózek, K. Heinonen, 2000, International journal of hematology.

Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications

M. Caligiuri, C. Bloomfield, G. Marcucci, 1999, Annals of Hematology.

The clinical significance of karyotype in acute myelogenous leukemia.

C. Bloomfield, J. Rowley, A. de la Chapelle, 1989, Cancer genetics and cytogenetics.

Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells

C. Bloomfield, S. Volinia, R. Garzon, 2019, Leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

C. Bloomfield, G. Petroni, N. Nissen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

Guido Marcucci, Stefano Volinia, Andrew J. Carroll, 2014, Proceedings of the National Academy of Sciences.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2012, Blood.

Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).

C. Bloomfield, C. Schiffer, R. Larson, 1992, Blood.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Guido Marcucci, Stefano Volinia, Jessica Kohlschmidt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality

C. Bloomfield, K. Mrózek, A. Niezabitowski, 2001, Genes, chromosomes & cancer.

Abstracts of workshop presentations (Part 11 of 13)

R. L. Miller, D. Cox, C. Bloomfield, 1985 .

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2007, The Journal of clinical investigation.

FTY 720 , a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome – positive acute lymphocytic leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2007 .

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

C. Bloomfield, J. Byrd, K. Mrózek, 2016, Haematologica.

arising in the setting of severe congenital neutropenia Distinct patterns of mutations occurring in de novo AML versus AML

E. Mardis, C. Bloomfield, M. McLellan, 2013 .

Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

R. Wilson, E. Mardis, M. Caligiuri, 2007, Blood.

NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation

Sandya Liyanarachchi, Guido Marcucci, Wenrui Duan, 2014, Proceedings of the National Academy of Sciences.

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

C. Bloomfield, M. Grever, J. Byrd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance

C. Bloomfield, K. Mrózek, 2015 .

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Genes, chromosomes & cancer.

Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.

C. Bloomfield, F. Appelbaum, C. Willman, 1997, Blood.

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804

C. Bloomfield, R. Larson, W. Stock, 2009, Cancer Chemotherapy and Pharmacology.

Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.

Guido Marcucci, Christoph Plass, Thomas D. Schmittgen, 2008, Cancer research.

Expression in Acute Myeloid Leukemia α Epigenetic Modification of CCAAT / Enhancer Binding Protein

Thomas D. Schmittgen, C. Bloomfield, C. Plass, 2008 .

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

C. Bloomfield, P. Paschka, K. Mrózek, 2008, Current opinion in oncology.

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.

M. Caligiuri, C. Bloomfield, C. Plass, 2008, Blood.

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

Tamara J. Blätte, C. Bloomfield, L. Bullinger, 2021, Blood.

The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.

Valentina R Minciacchi, C. Bloomfield, C. Plass, 2021, Blood.

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation

Michael F Clarke, C. Bloomfield, A. Look, 2007, Nature Medicine.

Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia

C. Bloomfield, M. Cazzola, M. L. Beau, 2016 .

Additional cytogenetic abnormalities in adults with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B

C. Bloomfield, R. Larson, K. Mrózek, 2004, British journal of haematology.

Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.

C. Bloomfield, R. Larson, M. L. Le Beau, 1999, Blood.

Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24

C. Bloomfield, C. Schiffer, M. L. Le Beau, 1992, American journal of hematology.

Analysis of activated and nonactivated cytoplasmic glucocorticoid-receptor complexes from human leukemia cells by rapid DNA-diethylaminoethyl minicolumn chromatography.

C. Bloomfield, N. Holbrook, A. Munck, 1983, Cancer research.

PROLONGED MAINTAINED REMISSIONS OF ADULT ACUTE NON-LYMPHOCYTIC LEUKAEMIA

C. Bloomfield, B. Peterson, 1977, The Lancet.

Daunorubicin‐prednisone remission induction with hydroxyurea maintenance in acute non‐lymphocytic leukemia

C. Bloomfield, B. Kennedy, R. Brunning, 1973, Cancer.

Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy

C. Bloomfield, S. Levitt, A. Goldman, 1980, Cancer.

Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma.

C. Bloomfield, J. Kersey, K. Gajl-Peczalska, 1979, The New England journal of medicine.

Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases.

C. Bloomfield, R. Brunning, R. Mckenna, 1975, Annals of internal medicine.

ALL-1 partial duplication in acute leukemia.

M. Caligiuri, C. Bloomfield, C. Croce, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations.

M. Caligiuri, C. Bloomfield, C. Croce, 1994, Cancer research.

Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia

M. Caligiuri, C. Bloomfield, A. Ferrando, 2004, The Lancet.

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

C. Bloomfield, R. Garzon, S. Liyanarachchi, 2016, Cancer discovery.

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Edward J. Lee, C. Bloomfield, R. Larson, 1998, Blood.

Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies.

C. Bloomfield, T. Lebien, J. Minowada, 1985, Blood.

Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia.

C. Bloomfield, D. Hossfeld, A. Chapelle, 1984, Cancer genetics and cytogenetics.

Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies.

C. Bloomfield, F. Speleman, J. Vandesompele, 2004, Blood.

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma

Edward J. Lee, C. Bloomfield, R. Larson, 2004, Cancer.

Clinical importance of cytogenetics in acute myeloid leukaemia.

C. Bloomfield, K. Mrózek, K. Heinonen, 2001, Best practice & research. Clinical haematology.

Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Third International Workshop on Chromosomes in Leukemia.

C. Bloomfield, J. Rowley, J. Whang‐Peng, 1983, Cancer research.

Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance

C. Bloomfield, D. Arthur, M. Nesbit, 1982 .

Prognostic significance of the Philadelphia chromosome in acute lymphocytic leukemia

C. Bloomfield, Kendall A. Smith, R. Brunning, 1980 .

Chromosomal Abnormalities in Acute Lymphoblastic Leukemia1

C. Bloomfield, D. Arthur, T. Lebien, 1981 .

Glucocorticoid Receptors in Adult Acute Lymphoblastic Leukemia1

C. Bloomfield, Kendall A. Smith, A. Munck, 2006 .

Covalent labeling of rat thymocyte and human lymphoid glucocorticoid receptor.

C. Bloomfield, H. Eisen, C. M. Foster, 1983, Cancer research.

Glucocorticoid receptors and in vitro responses to glucocorticoid in acute nonlymphocytic leukemia.

C. Bloomfield, G. Crabtree, K. Smith, 1981, Cancer research.

Stabilization of labile glucocorticoid-receptor complexes from acute nonlymphocytic leukemia cells by a factor from chronic lymphocytic leukemia cells.

C. Bloomfield, N. Holbrook, A. Munck, 1984, Cancer research.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Guido Marcucci, Marco Marra, Zhaohui Gu, 2016, Nature Communications.

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

Heather L. Mulder, Michael C. Rusch, Michael N. Edmonson, 2016, Nature Genetics.

Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission.

C. Bloomfield, R. Brunning, B. Peterson, 1987, The American journal of medicine.

Prognostic factors at relapse for adults with acute myeloid leukemia

C. Bloomfield, B. Peterson, D. Hurd, 1990, American journal of hematology.

Response of therapy-associated acute nonlymphocytic leukemia to intensive induction chemotherapy.

C. Bloomfield, B. Peterson, D. Hurd, 1985, Medical and pediatric oncology.

15;17 Translocation in acute promyelocytic leukemia.

C. Bloomfield, D. Arthur, B. Peterson, 1982, Cancer genetics and cytogenetics.

Hypocellular acute leukemia.

C. Bloomfield, R. Mckenna, R. Howe, 1982, The American journal of medicine.

Re-induction of complete remissions in adults with acute non-lymphocytic leukemia.

C. Bloomfield, B. Peterson, 1981, Leukemia research.

Treatment of adult acute nonlymphocytic leukemia--1978.

C. Bloomfield, 1978, Archives of internal medicine.

Disease-Free Survival in Acute Nonlymphocytic Leukemia

C. Bloomfield, B. Peterson, 2016 .

Acute granulocytic leukemia in elderly patients.

C. Bloomfield, A. Theologides, 1973, JAMA.

Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review

C. Bloomfield, K. Mrózek, G. Marcucci, 2007, British journal of haematology.

Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sp1/NF κ B/HDAC/ miR-29b Regulatory Network in KIT-driven Myeloid Leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2010 .

Use of Bootstrapping to Evaluate Infrequent Genetic Abnormalities as Prognostic Factors for Survival in Human Acute Leukemias

C. Bloomfield, P. Reese, David D. Lawrence, 1992 .

Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome

M. Loh, J. Downing, C. Bloomfield, 2013 .

Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).

C. Bloomfield, J. Byrd, D. Arthur, 1997, Blood.

Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.

C. Bloomfield, M. Czuczman, C. Schiffer, 1999, Blood.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Trisomy 13: A New Recurring Chromosome Abnormality in Acute Leukemia

C. Bloomfield, H. Döhner, J. Testa, 1990 .

Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions

M. Caligiuri, C. Bloomfield, K. Mrózek, 2006, Clinical Cancer Research.

Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line.

M. Caligiuri, C. Bloomfield, C. Plass, 2002, Blood.

Prolonged S ingle-Agent V ersus C ombination C hemotherapy i n Indolent F ollicular L ymphomas: A S tudy o f t he C ancer a nd Leukemia G roup B

C. Bloomfield, G. Petroni, N. Nissen, 2003 .

MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.

C. Bloomfield, M. Radmacher, C. Croce, 2009, Best practice & research. Clinical haematology.

Four new recurring translocations in non-Hodgkin lymphoma.

C. Bloomfield, D. Arthur, B. Peterson, 1989, Blood.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

Report of the Committee on Chromosome Rearrangements in Neoplasia and on Fragile Sites.

C. Bloomfield, R. Berger, G. Sutherland, 1985, Cytogenetics and cell genetics.

Chemotherapy With cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for hodgkin disease: Fourteen‐year follow‐up results

C. Bloomfield, K. Dusenbery, B. Peterson, 1988, American journal of hematology.

B-cell markers on lymphoblasts in acute lymphoblastic leukaemia.

C. Bloomfield, J. Kersey, M. Nesbit, 1974, Clinical and experimental immunology.

DNA nucleotidylexotransferase of normal persons and leukemic patients.

C. Bloomfield, W. Yasmineh, B. Smith, 1980, Clinical chemistry.

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665

C. Bloomfield, R. Larson, C. Mullighan, 2016, Leukemia & lymphoma.

Sequential karyotypes in non‐Hodgkin lymphoma: Their nature and significance

C. Bloomfield, O. Garson, D. Arthur, 1990, Genes, chromosomes & cancer.

Cytogenetic studies of 21 patients with acute lymphoblastic leukemia in relapse.

C. Bloomfield, J. Rowley, A. de la Chapelle, 1989, Cancer genetics and cytogenetics.

Morphologic and cytochemical characterization of adult lymphoid leukemias which express myeloid antigen.

C. Bloomfield, R. Mick, F. Davey, 1988, Leukemia.

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials

C. Bloomfield, E. Estey, R. Larson, 2013, Cancer.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.

C. Bloomfield, J. Byrd, R. Garzon, 2021, Blood advances.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Ulrich Mansmann, Xinan Yang, Guido Marcucci, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.

C. Bloomfield, R. Larson, K. Mrózek, 2020, Blood advances.

Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.

C. Bloomfield, K. Metzeler, 2017, Advances in experimental medicine and biology.

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

C. Bloomfield, R. Kittles, P. Paschka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007 .

ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements.

M. Caligiuri, C. Bloomfield, C. Croce, 1994, Cancer research.

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.

M. Loh, C. Bloomfield, M. Relling, 2014, Blood.

Acquired copy number alterations in adult acute myeloid leukemia genomes

J. Kitzman, R. Wilson, R. Fulton, 2009, Proceedings of the National Academy of Sciences.

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Yi Ning, Kellie J Archer, C. Bloomfield, 2006, Blood.

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia

C. Bloomfield, J. Byrd, R. Garzon, 2019, Haematologica.

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).

C. Bloomfield, J. Byrd, R. Vij, 2021, Blood advances.

Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364 Value of Immunophenotype in Intensively Treated Adult Acute

C. Bloomfield, M. Czuczman, R. Larson, 2011 .

Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.

C. Bloomfield, C. Schiffer, S. George, 1994, Blood.

The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease.

C. Bloomfield, T. Pajak, N. Nissen, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Leukemia.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.

C. Bloomfield, K. Mrózek, 2008, Journal of the National Cancer Institute. Monographs.

Family history of cancer and incidence of acute leukemia in adults.

Dale P Sandler, Andrew F Olshan, Charles Poole, 2002, American journal of epidemiology.

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

C. Bloomfield, R. Larson, W. Stock, 2014, Haematologica.

Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.

C. Bloomfield, C. Schiffer, J. Griffin, 1986, Blood.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant

C. Bloomfield, R. Brunning, R. Mckenna, 1982, British journal of haematology.

Abstracts of workshop presentations (Part 1 of 13)

R. L. Miller, D. Cox, C. Bloomfield, 1985 .

Extended field radiotherapy in non-Hodgkin's lymphoma.

C. Bloomfield, S. Levitt, M. Nesbit, 1976, Radiology.

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years

C. Bloomfield, J. Byrd, A. de la Chapelle, 2020, Leukemia.

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.

C. Bloomfield, K. Grzeschik, T. Möröy, 2007, Blood.

Leukemia Group B Study 9511 improved outcomes in adult acute lymphoblastic leukemia: Cancer and Effective asparagine depletion with pegylated asparaginase results in

C. Bloomfield, R. Larson, J. Kurtzberg, 2013 .

Myelodysplastic syndromes, version 2.2015.

C. Bloomfield, H. Deeg, R. Bejar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Bone marrow involvement in Burkitt's lymphoma

C. Bloomfield, R. Brunning, P. Coccia, 1977, Cancer.

Use of monoclonal antibodies, morphology, and cytochemistry to probe the cellular heterogeneity of acute leukemia and lymphoma.

C. Bloomfield, T. Lebien, J. Kersey, 1981, Cancer research.

Chromosome abnormalities in acute nonlymphocytic leukemia: clinical and biologic significance.

C. Bloomfield, A. de la Chapelle, 1987, Seminars in oncology.

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

C. Bloomfield, J. Byrd, K. Döhner, 2020, Blood advances.

Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia

C. Bloomfield, L. Lee, G. Marcucci, 2016, Oncotarget.

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.

M. Caligiuri, C. Bloomfield, M. Grever, 2003, Blood.

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 1998, Cancer research.

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

Salam A. Assi, C. Bloomfield, N. Nassar, 2016, Leukemia.

tyrosine kinase genes of patients with de novo acute myeloid leukemia Somatic mutations and germline sequence variants in the expressed

R. Wilson, C. Bloomfield, M. McLellan, 2013 .

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

C. Bloomfield, R. Larson, F. Appelbaum, 2014, Leukemia & lymphoma.

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.

Edward J. Lee, C. Bloomfield, R. Larson, 2004, Blood.

Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect

C. Bloomfield, D. Bell, J. Taylor, 1996, The Lancet.

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

Clara D. Bloomfield, C. Bloomfield, J. Diebold, 2000, The hematology journal : the official journal of the European Haematology Association.

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2008, Blood.

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 2003, Blood.

Multivariate analysis of prognostic factors in the non‐Hodgkin's malignant lymphomas

C. Bloomfield, R. Brunning, A. Goldman, 1974, Cancer.

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

K. Livak, C. Bloomfield, B. Yeap, 2003, Blood.

Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

C. Bloomfield, M. Radmacher, K. Döhner, 2012, Proceedings of the National Academy of Sciences.

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

C. Bloomfield, R. Larson, E. Vellenga, 2010, Blood.

Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.

C. Bloomfield, E. Thiel, W. Hofmann, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia.

M. Caligiuri, C. Bloomfield, N. Zeleznik-Le, 2001, Cancer research.

EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia

C. Bloomfield, R. Garzon, Changxian Shen, 2019, Clinical Cancer Research.

Intronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway

C. Bloomfield, A. de la Chapelle, J. Markowitz, 2014, Science Signaling.

Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia.

C. Bloomfield, K. Mrózek, 2006, Hematology. American Society of Hematology. Education Program.

Molecular cytogenetic characterization of the KG‐1 and KG‐1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization

C. Bloomfield, K. Mrózek, S. M. Tanner, 2003, Genes, chromosomes & cancer.

Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.

C. Bloomfield, J. Byrd, M. Qumsiyeh, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Klaus H. Metzeler, Guido Marcucci, Stefano Volinia, 2013, Leukemia.

5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.

C. Bloomfield, B. Peterson, A. Gottlieb, 1982, Cancer treatment reports.

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances

C. Bloomfield, H. Döhner, K. Mrózek, 2007, Current opinion in hematology.

Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 1998, British journal of haematology.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

C. Bloomfield, M. Radmacher, P. Paschka, 2009 .

High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.

C. Bloomfield, K. Mrózek, M. Baer, 1993, Seminars in oncology.

The clinical significance of chromosomal changes in acute leukemia.

C. Bloomfield, 1985, Progress in clinical and biological research.

Abstracts of workshop presentations (Part 13 of 13)

R. L. Miller, D. Cox, C. Bloomfield, 1985 .

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

C. Bloomfield, J. Byrd, K. Metzeler, 2018, Blood advances.

A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes

R. Wilson, E. Mardis, M. Caligiuri, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced‐stage disease

C. Bloomfield, N. Nissen, A. Gottlieb, 1993, Cancer.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

C. Bloomfield, R. Larson, K. Mrózek, 2019, Leukemia.

Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A

C. Bloomfield, J. Byrd, A. de la Chapelle, 2020, Proceedings of the National Academy of Sciences.

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2002, International journal of oncology.

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

C. Bloomfield, K. Mrózek, R. Mayer, 1997, Blood.

A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.

C. Bloomfield, B. Peterson, B. Poiesz, 1992, Journal of immunotherapy.

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)

Tamara J. Blätte, C. Bloomfield, L. Bullinger, 2018, Blood.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

C. Bloomfield, R. Larson, S. Mandrekar, 2017, Blood advances.

Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma

C. Bloomfield, E. Henderson, D. Budman, 2004, Investigational new drugs.

Sister chromatid exchange in patients with viral disease.

C. Bloomfield, J. Červenka, K. Kurvink, 1978, Experimental cell research.

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

C. Bloomfield, L. Bullinger, K. Döhner, 2021, Leukemia.

FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

C. Bloomfield, K. Döhner, H. Döhner, 2018, Blood.

Der(16)t(1;16) is a secondary chromosome aberration in at least eighteen different types of human cancer

C. Bloomfield, K. Mrózek, 1998, Genes, chromosomes & cancer.

New recurrent structural chromosome aberrations in non-Hodgkin's lymphoma.

C. Bloomfield, K. Mrózek, 1996, International journal of oncology.

Radical radiation therapy in the treatment of laparotomy staged Hodgkin's disease patients

C. Bloomfield, S. Levitt, C. Lee, 1984 .

Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)

C. Bloomfield, L. Bullinger, K. Döhner, 2018, Blood.

Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB‐M6): A CALGB study

C. Bloomfield, J. Griffin, R. Mayer, 1995, American journal of hematology.

Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia.

C. Bloomfield, O. Garson, R. Berger, 1994, Cancer genetics and cytogenetics.

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

C. Bloomfield, P. Paschka, R. Larson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defect in Acute Myeloid Leukemia with Trisomy 11 as a Recurrent Molecular ALL 1 Partial Tandem Duplication of Updated

M. Caligiuri, C. Bloomfield, C. Croce, 2006 .

Detection of Unique ALLÃ(cid:141) (MLL) Fusion Transcripts in Normal Human Bone Marrow and Blood: Distinct Origin of Normal versus Leukemic ALLÃ(cid:141) Fusion Transcripts1

C. Bloomfield, G. Marcucci, Matthew, 2006 .

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.

Stefano Volinia, Jessica Kohlschmidt, Karl Kroll, 2017, Cancer research.

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

C. Bloomfield, J. Byrd, R. Larson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin disease/lymphoma.

C. Bloomfield, R. Advani, P. Bierman, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

C. Bloomfield, W. Hiddemann, H. Döhner, 2014, Haematologica.

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

C. Bloomfield, J. Byrd, A. de la Chapelle, 2018, Leukemia.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

C. Bloomfield, L. Garraway, Judit Jané-Valbuena, 2018, Blood advances.

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

C. Bloomfield, J. Byrd, R. Garzon, 2020 .

The revised French-American-British classification of acute myeloid leukemia: is new better?

C. Bloomfield, R. Brunning, 1985, Annals of internal medicine.

ME Jr Nesbit characteristics and prognostic significance Translocation 4 ; 11 in acute lymphoblastic leukemia : clinical

C. Bloomfield, D. Arthur, M. Nesbit, 2005 .

Translocation 4 ; ! ! in Acute Lymphoblastic Leukemia : Clinical Characteristics and Prognostic Significance

C. Bloomfield, D. Arthur, M. Nesbit, 2005 .

Acute myeloid leukemia with adverse cytogenetic risk.

C. Bloomfield, K. Mrózek, 2012, Oncology.

The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal masses.

C. Bloomfield, S. Levitt, A. Goldman, 1981, International journal of radiation oncology, biology, physics.

Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non‐Hodgkin's lymphomas cancer and leukemia group B study 7851

C. Bloomfield, L. Norton, N. Nissen, 1990, Cancer.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Ashley D. Hill, M. Loh, J. Downing, 2019, Nature Genetics.

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia

Nancy F. Hansen, M. Caligiuri, C. Bloomfield, 2015, Leukemia.

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2009 .

Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

C. Bloomfield, K. Owzar, R. Larson, 2012 .

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)

C. Bloomfield, J. Byrd, R. Larson, 2015 .

Abstracts of workshop presentations (Part 3 of 16)

J. N. Guidi, C. Bloomfield, K. Kidd, 1987 .

Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts.

M. Caligiuri, C. Bloomfield, G. Marcucci, 1998, Cancer research.

Band 11 q 13 is nonrandomly rearranged in hibernomas

C. Bloomfield, C. Karakousis, Krzysztof Mrœzek, 1994, Genes, chromosomes & cancer.

Dietary Intake, Food Processing, and Cooking Methods Among Amish and Non-Amish Adults Living in Ohio Appalachia: Relevance to Nutritional Risk Factors for Cancer

C. Bloomfield, M. Katz, E. Paskett, 2011, Nutrition and cancer.

Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.

C. Bloomfield, K. Rai, R. Silver, 1995, Leukemia.

Cytogenetics of non-Hodgkin's lymphoma.

C. Bloomfield, E. Levine, 1990, Journal of the National Cancer Institute. Monographs.

Der(16)T(1-16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia-chromosome-positive acute lymphoblastic-leukemia.

C. Bloomfield, P. Koduru, F. Davey, 1995, International journal of oncology.

Immunophenotyping in the diagnosis and classification of acute lymphoblastic leukemia.

C. Bloomfield, I. Royston, R. Sobol, 1988, Clinics in laboratory medicine.

Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study.

C. Bloomfield, R. Kittles, P. Paschka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNA expression in acute myeloid leukemia

C. Bloomfield, M. Radmacher, K. Mrózek, 2009, Current hematologic malignancy reports.

Lymphography as a guide during laparotomy in Hodgkin's and non-Hodgkin's lymphomas.

C. Bloomfield, K. Amplatz, S. Levitt, 1977, Acta radiologica: therapy, physics, biology.

patients with de novo acute myeloid leukemia : results from Cancer and success , cumulative incidence of relapse , and overall survival in adult Pretreatment cytogenetic abnormalities are predictive of induction

C. Bloomfield, J. Byrd, R. Larson, 2002 .

Effects of Glucocorticoid Administration on Lymphocyte Glucocorticoid Receptors

C. Bloomfield, K. Smith, A. Munck, 2005 .

A precision medicine classification for treatment of acute myeloid leukemia in older patients

C. Bloomfield, J. Byrd, R. Levine, 2021, Journal of Hematology & Oncology.

Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia

M. Caligiuri, C. Bloomfield, C. Croce, 2015, Leukemia.

Molecular signatures in acute myeloid leukemia

C. Bloomfield, M. Radmacher, K. Mrózek, 2009, Current opinion in hematology.

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.

C. Bloomfield, J. Byrd, R. Larson, 2004, Annals of hematology.

Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.

C. Bloomfield, M. L. Le Beau, W. Stock, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults

C. Bloomfield, Cheng Cheng, J. Radich, 2015 .

Abstracts of workshop presentations (Part 12 of 13)

R. L. Miller, D. Cox, C. Bloomfield, 1985 .

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107

C. Bloomfield, R. Larson, R. Stone, 2008, Leukemia & lymphoma.

Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.

C. Bloomfield, B. Göttgens, J. Schütte, 2013, Blood.

Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q

C. Bloomfield, K. Mrózek, K. Heinonen, 2002, Genes, chromosomes & cancer.

Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.

C. Bloomfield, B. Cheson, R. Simon, 1990, Medical and pediatric oncology.

The Use of Daily Aspirin, Nutritional Supplements and Alternative Medications among Amish and non-Amish living in Ohio Appalachia

C. Bloomfield, M. Katz, E. Paskett, 2012, Nutrition and cancer.

Abstracts of workshop presentations (Part 4 of 13)

R. L. Miller, D. Cox, C. Bloomfield, 1985 .

Management of patients with acute non-lymphocytic leukemia who fail first cycle of induction therapy.

C. Bloomfield, B. Peterson, D. Hurd, 1981, Leukemia research.

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2011 .

Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001

C. Bloomfield, K. Owzar, R. Larson, 2011 .

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Leukemia.

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2008, International journal of oncology.

miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53

M. Caligiuri, C. Bloomfield, M. Radmacher, 2014 .

Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461

C. Bloomfield, R. Larson, K. Mrózek, 2004 .

The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas.

C. Bloomfield, B. Cheson, R. Simon, 1988, Annals of internal medicine.

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)-Preliminary results of CALGB 10001.

C. Bloomfield, K. Owzar, R. Larson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop †

C. Bloomfield, S. Raimondi, K. Mrózek, 2002, Genes, chromosomes & cancer.

B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy.

C. Bloomfield, J. Kersey, K. Gajl-Peczalska, 1976, Clinical and experimental immunology.

High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710)

C. Bloomfield, R. Larson, W. Stock, 2008 .

Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour

C. Bloomfield, K. Mrózek, P. Nagesh Rao, 1996, British journal of haematology.

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine

C. Bloomfield, C. Reynolds, J. Sklar, 2003, Cancer.

Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

C. Bloomfield, C. Croce, R. Garzon, 2018, Blood.

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

C. Bloomfield, J. Byrd, K. Metzeler, 2021, Haematologica.

Group B studies A comparison of Children's Cancer Group and Cancer and Leukemia acute lymphoblastic leukemia treated on cooperative group protocols? What determines the outcomes for adolescents and young adults with

C. Bloomfield, J. Vardiman, P. Gaynon, 2011 .

Introduction: Acute Myeloid Leukemia

C. Bloomfield, K. Döhner, H. Döhner, 2008 .

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

C. Bloomfield, K. Döhner, R. Schlenk, 2017 .

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

C. Bloomfield, K. Döhner, R. Schlenk, 2017 .

myeloid leukemia in acute microRNA-181a up-regulates expression of the antileukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP

C. Bloomfield, J. Byrd, L. J. Lee, 2013 .

Ramasamy myeloid leukemia in acute microRNA-181 a upregulates expression of the antileukemic-p 30 protein α Lenalidomide-mediated enhanced translation of C / EBP

Wu, Krzysztof, Santhanam, 2012 .

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

C. Bloomfield, Xiaochun Li, W. Woods, 2005 .

Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia.

C. Bloomfield, M. Radmacher, E. Thiel, 2005 .

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

C. Bloomfield, J. Byrd, R. Vij, 2005 .

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Benchmarks in clinical productivity: a national comprehensive cancer network survey.

C. Bloomfield, S. Perkel, M. Waldinger, 2007, Journal of oncology practice.

All-trans-Retinoic Acid in Acute Promyelocytic Leukemia

C. Bloomfield, F. Appelbaum, C. Willman, 2000 .

Cytogenetics of Acute Leukemia

C. Bloomfield, S. Raimondi, K. Mrózek, 2013 .

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia

M. Caligiuri, C. Bloomfield, L. J. Lee, 2015, Leukemia.

Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

C. Bloomfield, R. Larson, A. Chanan-Khan, 2015, British journal of haematology.

Trisomy 13: a new recurring chromosome abnormality in acute leukemia.

C. Bloomfield, H. Döhner, J. Testa, 1990, Blood.

Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia.

I Royston, C. Bloomfield, J. Griffin, 1987, The New England journal of medicine.

G Flandrin, J Diebold, C. Bloomfield, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Chromosome abnormalities in secondary myelodysplastic syndromes.

C. Bloomfield, 2009, Scandinavian journal of haematology. Supplementum.

CHROMOSOMAL ABNORMALITIES IN NON-HODGKIN'S MALIGNANT LYMPHOMA11This work was supported by the Coleman Leukemia Research Fund and by NCI grant 17034.

C. Bloomfield, D. Arthur, B. Peterson, 1982 .

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

C. Bloomfield, J. Diebold, N. Harris, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term survival of patients with acute myeloid leukemia

C. Bloomfield, J. Rowley, O. Garson, 1997, Cancer.

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

C. Bloomfield, R. Larson, W. Stock, 2012 .

Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia

C. Bloomfield, J. Byrd, A. Bottoni, 2018, Leukemia & lymphoma.

Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Leukemia.

asH members named Fellows of the american academy of arts and sciences

C. Bloomfield, 2022 .

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

C. Bloomfield, K. Metzeler, R. Garzon, 2012, Leukemia.

Cytogenetics of indolent lymphomas.

C. Bloomfield, K. Mrózek, 1993, Seminars in oncology.

Clinical significance of the cytogenetics of acute leukemias.

C. Bloomfield, J. Machnicki, 1990, Oncology.

Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry

C. Bloomfield, C. Schiffer, K. Mrózek, 1998, Leukemia.

A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification

C. Bloomfield, J. Byrd, R. Garzon, 2018, Blood.

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010 .

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia

C. Bloomfield, C. Croce, S. Volinia, 2017, Oncotarget.

reveal therapeutic targets in transgenic ERG myeloid leukemia Genome-scale expression and transcription factor binding profiles

C. Bloomfield, S. Kinston, R. Hannah, 2013 .

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

C. Bloomfield, H. Gundacker, S. Raimondi, 2006, Leukemia.

Clinical Trials and Observations

C. Bloomfield, L. Staudt, A. Rosenwald, 2005 .

Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone.

C. Bloomfield, B. Kennedy, B. Peterson, 1981, Archives of internal medicine.

Significance of Haematological Parameters in the Non‐Hodgkin's Malignant Lymphomas

C. Bloomfield, C. Bloomfield, R. Brunning, 1976, British Journal of Haematology.

Secondary myelodysplastic syndromes and leukaemias.

C. Bloomfield, E. Levine, 1986, Clinics in haematology.

recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults:

C. Bloomfield, E. Estey, T. Naoe, 2010 .

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2010 .

Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay

M. Caligiuri, C. Bloomfield, G. Marcucci, 1998, Leukemia.

Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, M. Radmacher, P. Paschka, 2007 .

MYC diffuse large B-cell lymphoma is not salvaged by classical RICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

C. Bloomfield, M. Qumsiyeh, J. Vardiman, 2012 .

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia

C. Bloomfield, P. Paschka, K. Mrózek, 2008, Current opinion in oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

C. Bloomfield, Hillard M. Lazarus, Donald Small, 2006 .

Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia

M. Caligiuri, C. Bloomfield, K. Döhner, 2001, Leukemia.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

University of Birmingham UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

Salam A. Assi, C. Bloomfield, C. Bonifer, 2015 .

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2

Karl W. Kroll, C. Bloomfield, J. Byrd, 2016, Leukemia.

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Genes, chromosomes & cancer.

Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Cancer research.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells

C. Bloomfield, S. Volinia, R. Garzon, 2019, Leukemia.

Large mediastinal masses in Hodgkin's disease: Comparison of the results of whole lung and regular mantle field irradiation

C. Bloomfield, S. Levitt, M. Nesbit, 1979 .

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

C. Bloomfield, J. Byrd, C. Croce, 2009, Blood.

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Clinical Cancer Research.

A Pluripotency Signature Predicts Histologic Transformation and Influences Survival in Follicular Lymphoma Patients

C. Bloomfield, M. Qumsiyeh, A. Ruppert, 2022 .

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

M. Caligiuri, C. Bloomfield, J. Byrd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).

C. Bloomfield, M. Radmacher, R. Larson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, Lisheng Wang, 2007, Blood.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

C. Bloomfield, M. Buyse, R. Larson, 2011, Blood.

Morphologic and cytochemical characteristics of acute promyelocytic leukemia

C. Bloomfield, C. Schiffer, J. Griffin, 1989, American journal of hematology.

Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations

C. Bloomfield, J. Byrd, J. Kolitz, 2020, Leukemia.

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

C. Bloomfield, J. Byrd, S. Volinia, 2016, Leukemia.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2006, Blood.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma

C. Bloomfield, G. Marcucci, K. Maharry, 2009 .

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.

C. Bloomfield, M. Relling, C. Pui, 2014, Blood.

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

C. Bloomfield, R. Vij, R. Larson, 2006 .

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

VP 16-213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features.

C. Bloomfield, B. Peterson, D. Hurd, 1981, Medical and pediatric oncology.

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

M. Caligiuri, C. Bloomfield, R. Vij, 2007 .

Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q).

C. Bloomfield, A. Look, J. Issa, 2004 .

Cancer screening practices among Amish and non-Amish adults living in Ohio Appalachia.

C. Bloomfield, S. Lemeshow, M. Katz, 2011, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.